

## Possible Effect of *Cinnamomum camphora* on Pain Amelioration and Pain Threshold in Mechanically Induced Pain in Female Wistar Rats

### ABSTRACT

**Background:** Camphor, a long-standing chemical used in various home treatments, has been extensively studied for its antibacterial, antipruritic, and contraceptive properties, and is a key ingredient in topical home treatments. The study investigated the possible effect of *Cinnamomum camphora* essential oil on pain amelioration and pain threshold in mechanically induced pain in female Wistar rats.

**Method:** Five groups of rats were selected. Group 1 which was the control group was administered with water, groups 2, 3, 4, and 5 were administered with 0.2ml re oil, 0.4ml *Cinnamomum camphora* oil, 0.6ml *Cinnamomum camphora* oil and piroxicam respectively for 4 weeks. They were also exposed to all tiers of pain tests (passive avoidance test, analgesic meter, and tail clip).

**Results:** Group 2 showed a significant increase in avoidance time, a significant increase in pain threshold, and a significant decrease in pain sensitivity compared to the control group. The reverse was the case of group 4 when compared to the control group. Interestingly, the effects of *C. camphora*oil were more on the low-dose group than on the high-dose group.

**Conclusion:** These results suggest that *C. camphora*has an analgesic effect and is dose-dependent.

Keywords: pain, pain threshold, *C. camphora*, pain amelioration, female

## Introduction

The discovery of novel pharmaceuticals is primarily reliant on medicinal plants. Camphor is well-known as a key component in topical home remedies for a variety of symptoms, and its use is widely accepted around the world due to its long history as an antiseptic, antipruritic, rubefacient, abortifacient, aphrodisiac, contraceptive, and lactation suppressant. Because of its long history of use, this drug has been the focus of various scientific examinations into its action and how it is metabolized in both human and animal bodies [1].

Camphor (*Cinnamomum camphora*) is a white, crystalline material with a strong odor and pungent taste obtained from the wood of camphor laurel (*Cinnamomum camphora*) and other laurel-related species. The camphor tree (*Cinnamomum camphora*) is a member of the Lauraceae family and is known to be native to China, India, Mongolia, Japan, and Taiwan. A variation of this aromatic evergreen tree is grown in the Southern United States, particularly in Florida [2, 3].

Modern pharmaceutical technologies give a theoretical basis for the performance of C. camphor, which has long been utilized in traditional medicine [4]. According to current research, the pharmacological effects are primarily obtained from *C. camphora* essential oils. Because of technological advancements, essential oils may be isolated from various portions of *C. camphora*, and components of essential oils with pharmacological properties can be separated and purified. Essential oils are mostly derived through distillation. The tree's wood, twigs, and bark are steam distilled, purified, and sublimated to produce camphor [2]. Camphor is readily absorbed via the skin and can be administered via injection, inhalation, or ingestion [5]. Camphor comes in various chemical types, each with a different essential oil content [6]. *Cinnamomum camphora* leaves include camphor as the major component, as well as cineol, linalool, eugenol, limonene, safrole,  $\alpha$ -pinene,  $\beta$ -pinene,  $\beta$ -myrcene,  $\alpha$ -humulene, p-cymene, nerolidol, borneol, camphene, and other components [7].

Pain is a major worldwide health problem, and treatment is complex [8]. Despite current scientific advances in pain medicines, many pain problems still lack potent, safe, and effective medications [9]. Furthermore, several of the existing pain medications have negative side effects [10]. As a result, both the pharmaceutical business and academics continue to prioritize optimizing existing pain medications and developing new ones [11]. In recent years, there has been a growing interest in herbal medicines as potential therapeutic agents for pain and inflammation.

Among them, the species *Cinnamomum camphora* (camphor) has a long tradition in classical medicine and has been used around the globe for diverse purposes such as; analgesic, antiseptic, antispasmodic, antipruritic, anti-inflammatory, anti-infective, rubefacient, contraceptive, mild expectorant, nasal decongestant, cough suppressant [12], spasmodic effects of circulatory and respiratory diseases, treatment for muscle pain, inflammation, and rheumatism in the pharmacy. While camphor has been shown to have various benefits, it can also be harmful in adults, causing congestion in the gastrointestinal tract, kidneys, and brain [13]. Symptoms of camphor poisoning in humans include nausea, vomiting, headache, disorientation, muscle excitability (producing tremors and twitching), convulsions, and delirium, depending on the dosage.

In a significant overdose, status epilepticus persists for several hours, eventually leading to unconsciousness and death from asphyxia or exhaustion, according to the International Program on Chemical Safety (IPCS) INCHEM [14]. A detailed assessment of the safety of ingesting camphor oil and its efficacy as a pain reliever is thus required and imperative [15].

This study aims to determine the possible effect of *Cinnamomum* on pain amelioration and pain threshold in mechanically induced pain in female Wistar rats.

## **Methodology**

### **Experimental design**

The animals were grouped into five groups

#### **Group 1**

This was the control group, which contained five rats. They were fed regular poultry chow and distilled water. There was no substance administered here. They were subjected to all levels of pain tests (passive avoidance test, analgesia meter, and tail clip) without receiving *Cinnamomum* medication.

#### **Group 2**

This group had five rats who were likewise fed standard poultry chow and distilled water. 0.2ml of *Cinnamomum camphora* essential oil was administered here. They were also subjected to all levels of pain testing (passive avoidance test, analgesic meter, tail clip).

### **Group 3**

This group consisted of five rats who were fed standard poultry chow and distilled water, and 0.4ml of *Cinnamomum camphora* essential oil was given. They were also subjected to all levels of pain testing (passive avoidance, analgesic meter, and tail clip).

### **Group 4**

This group consisted of five rats fed standard poultry chow and distilled water, and 0.6 ml of *Cinnamomum camphora* essential oil was given. They were also subjected to all levels of pain testing (passive avoidance, analgesia meter, and tail clip).

### **Group 5**

This group of five rats was fed standard poultry chow and distilled water, and 0.5ml of piroxicam was given. They were also subjected to all levels of pain testing (passive avoidance, analgesic meter, and tail clip).

### **Statistical analysis**

The ANOVA (Analysis of Variance) approach was used to analyze data across groups with varying treatment agent concentrations. SPSS version 23 and Microsoft Excel. The individual groups were then compared using the post-hoc multiple comparisons test (Newman Keuls test). The confidence level was set at 95%, and  $P < 0.05$  was considered significant. The data were provided as Mean Standard Error of Mean (S.E.M).

### **Results**

Table 1 above is the result from the passive avoidance test which revealed the mean value across the groups; at Week 1, Group 4 (0.6ml *Cinnamomum camphora*) showed a significant ( $p \leq 0.05$ ) decrease with a mean value of 70.20 when compared to the control group (group 1). At week 2, Group 2 (0.2ml *Cinnamomum camphora* group) showed a significant ( $p \leq 0.05$ ) increase in time of avoidance when compared to a control group with a mean value of 300.0. Group 3 (0.4ml *Cinnamomum camphora* group) also showed a significant ( $p \leq 0.05$ ) increase with a mean value of 300.0. Group 4 (0.6ml *Cinnamomum camphora* group) and 5

(piroxicam group) had no significant ( $p \leq 0.05$ ) difference in mean value when compared to the control group (group 1). At week 3, Group 2 (0.2ml *Cinnamomum camphora* group) and 4 (0.6ml *Cinnamomum camphora* group) had no significant ( $p \leq 0.05$ ) difference in mean value when compared to control group (group 1) while Group 3 (0.4ml *Cinnamomum camphora* group) and 5 (piroxicam group) showed significant ( $p \leq 0.05$ ) increase in time of avoidance test when compared to control group with mean value of 300.0 and 300.0 respectively.

Table 2 above revealed the mean values of task performance in the analgesymeter test. At week 1, Group 2 (0.2ml *Cinnamomum camphora* group), group 3 (0.4ml *Cinnamomum camphora* group) and group 5 (piroxicam group) showed no significant ( $p \leq 0.05$ ) difference in mean value when compared to control group (group 1). Group 4 (0.6ml *Cinnamomum camphora* group) had a significant ( $p \leq 0.05$ ) decrease with a mean value of 6.16. At week 2, Group 2 (0.2ml *Cinnamomum camphora* group) and 5 (piroxicam group) showed significant ( $p \leq 0.05$ ) increases when compared to a control group with mean values of 19.82 and 23.90 respectively. Group 3 (0.4ml *Cinnamomum camphora* group) and 4 (0.6ml *Cinnamomum camphora* group) had significant ( $p \leq 0.05$ ) decreases with mean values of 4.36 and 4.52 respectively. At week 3, Group 2 (0.2ml *Cinnamomum camphora* group), group 3 (0.4ml *Cinnamomum camphora* group) and group 5 (piroxicam group) showed no significant ( $p \leq 0.05$ ) difference in mean value. Group 4 (0.6ml *Cinnamomum camphora* group) had a significant ( $p \leq 0.05$ ) decrease with a mean value of 4.52.

Table 3 above shows the results obtained from the tail clip test. At week 1, there was no significant ( $p \leq 0.05$ ) difference in mean value in Group 2 (0.2ml *Cinnamomum camphora* group), group 3 (0.4ml *Cinnamomum camphora* group), group 4 (0.6ml *Cinnamomum camphora* group) and group 5 (piroxicam group). At week 2, Group 2 (0.2ml *Cinnamomum camphora* group), group 3 (0.4ml *Cinnamomum camphora* group) and group 5 (piroxicam group) showed no significant ( $p \leq 0.05$ ) difference in mean value when compared to control group (group 1). Group 4 (0.6ml *Cinnamomum camphora* group) had a significant ( $p \leq 0.05$ ) increase with a mean value of 92.4. At week 3, Group 2 (0.2ml *Cinnamomum camphora* group) had a significant ( $p \leq 0.05$ ) decrease with a mean value of 13.0. Group 3 (0.4ml *Cinnamomum camphora* group) and group 5 (piroxicam group) showed no significant ( $p \leq 0.05$ ) difference in mean value. Group 4 (0.6ml *Cinnamomum camphora* group) had a significant ( $p \leq 0.05$ ) increase with a mean value of 85.0.

### **Table 1**

## Table 2

## Table 3

## Discussion

Table 1 shows the assessment of the degree of alertness and learning behavior in the test and control groups using the passive avoidance test. Groups 2, 3, and 5 were given 0.2ml *Cinnamomum camphora* essential oil, 0.4ml *Cinnamomum camphora* essential oil, and 0.5ml piroxicam, respectively, and showed a significant increase in avoidance time, while group 4 (0.6ml *Cinnamomum camphora* essential oil) showed a significant decrease in avoidance time when compared to the control group. This large increase in avoidance time is thought to be caused by the presence of 1,8-cineole. *C. camphor* has five chemotypes based on the primary components of its leaf oil: isoborneol, camphor, 1,8-cineole, linalool, and borneol [16,17,18,19,20,21].

Table 1's results support the Farivar et al. [22] study on the protective effect of 1,8-cineole on learning and memory impairment. 1,8-cineole, which is induced by cerebral hypoperfusion in male rats, is known to be a potent antioxidant. The study found that administering 1,8-cineole significantly strengthened passive avoidance memory ( $P < 0.05$ ). Their studies also showed that 1,8-cineole improves behavioral abnormalities following I/R-induced brain damage. Another study conducted by Moss and Oliver [23] examined the potential pharmacological correlations between absorbed 1,8-cineole following exposure to rosemary scent, cognitive performance, and mood.

Performance on cognitive tasks was found to be substantially related to the concentration of absorbed 1,8-cineole after exposure to rosemary scent, with larger concentrations resulting in better performance. Table 2 shows the assessment of pain-bearing threshold and response in the test and control groups using an analgesic meter. Groups 2 and 5 showed a significant increase in pain threshold, while groups 3 and 4 showed a significant decrease in pain threshold when compared to the control group. This considerable improvement in pain tolerance is thought to be caused by the presence of camphor, 1,8-cineole, linalool, and borneol. The pain threshold, also known as the pain threshold, is the point along a curve of increasing perception of a stimulus at which pain becomes noticeable (IASP. "IASP Pain Terminology" 2013). According to Xu et al. [19], camphor has an analgesic effect by activating and subsequently desensitizing transient receptor potential vanilloid-1 (TRPV1). The combination of TRPV1 desensitization and TRPA1 suppression provides a novel

explanation for camphor's analgesic actions. Linalool has been demonstrated to reduce pain in models such as the acetic acid-induced writhing response, inflammatory pain, and the hot plate test in mice. The probable mechanism could be related to the inhibition of proinflammatory cytokines and the modulation of NMDA receptors. Topical use of borneol provided much more pain alleviation than placebo. Experiments in mice revealed that the TRPM8 channel could be the molecular target of borneol<sup>24,25,26</sup>. Zheng et al. [27] investigated the effects of 1,8-cineole on neuropathic pain mediated by the P2X2 receptor in the spinal cord dorsal horn and found that oral administration of 1,8-cineole inhibits over-expression of P2X2 receptor protein and mRNA in the spinal cord and dorsal horn in CCI rats.

Table 3 displays the assessment of pain sensitivity and response behavior in the test and control groups using the tail clip procedure. Group 2 (0.2ml *Cinnamomum camphora* essential oil) showed a significant decrease in pain sensitivity, while group 4 (0.6ml *Cinnamomum camphora* essential oil) showed a significant increase in pain sensitivity. This large decrease in pain sensitivity is thought to be caused by the presence of camphor, 1,8-cineole, linalool, and borneol, as observed in the research of Xu et al. [19]; Zheng et al. [27]; Fan et al. [24]; Peana et al. [25] and Wang et al. [26].

The significant decrease in avoidance time shown by group 4, a significant decrease in pain threshold shown by groups 3 and 4, and a significant increase in pain sensitivity shown by group 4 in tables 1, 2, and 3 respectively is suspected to be a result of increased dose of *Cinnamomum camphora* essential oil.

## **Conclusion**

The results obtained from the different test groups and control group using passive avoidance test, analgesymeter, and tail clip test showed a significant increase in avoidance time, a significant increase in pain threshold, and a significant decrease in pain sensitivity in group 2 which were administered with 0.2ml *Cinnamomum camphora* oil thereby indicating the analgesic effect of the essential oil. However, the reverse was found in group 4 which was administered with 0.6ml *Cinnamomum camphora* oil. Interestingly, the effects of *C. camphora* oil were more on the low-dose group than on the high-dose group. This study concludes that the analgesic effect of *Cinnamomum camphora* essential oil is due to the presence of camphor, 1,8-cineole, Linalool, and borneol in the oil and *Cinnamomum camphora* essential oil is dose-dependent. i.e it was more effective in the low dose group than the high dose group.

## RECOMMENDATION

It is therefore recommended that the analgesic use of *Cinnamomum camphora* oil should be done after the prescription of a safe dose by a health physician as it can be toxic when misused.

Further research should be carried out properly on *Cinnamomum camphora* to study the detailed mechanism of action in the body, the safe route of administration, and also the safe dose that can be taken to produce a positive effect.

## References

1. Lees P, Pelligand L, Giraud E, Toutain PL. A history of antimicrobial drugs in animals: Evolution and revolution. *Journal of Veterinary Pharmacology and Therapeutics*. 2021 Mar;44(2):137-71.
2. Sharma N. Folklore and modern pharmacology of camphor (*Cinnamomum camphora* Nees and Eberm): Review. *Scholars International Journal of Traditional and Complementary Medicine*. 2021;4(7):128-35.
3. Mahale BM, Mahale DS, Shaikh AZ. Natural Herbs used in normal Cough and Cold Conditions. *Research Journal of Pharmacognosy and Phytochemistry*. 2022;14(2):98-102.
4. Lee SH, Kim DS, Park SH, Park H. Phytochemistry and applications of *Cinnamomum camphora* essential oils. *Molecules*. 2022 Apr 22;27(9):2695.
5. BOURNVILLE D. PHYSIOLOGICAL AND THERAPEUTICAL RESEARCH ON THE MONOBROMIDE OF CAMPHOR. *The Practitioner: a Journal of Therapeutics and Public Health*: Vol. XIII. 2023 Dec 30:112.
6. Zhang T, Zheng Y, Fu C, Yang H, Liu X, Qiu F, Wang X, Wang Z. Chemical variation and environmental influence on essential oil of *Cinnamomum camphora*. *Molecules*. 2023 Jan 18;28(3):973.
7. Singh S, Chaurasia PK, Bharati SL, editors. *Pharmacological Aspects of Essential Oils: Current and Future Trends*.
8. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain*. 2020 Sep 1;161(9):1976-82.
9. Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, Burczynski ME, Crean C, Edwards R, Gaudilliere B, Hergenroeder GW. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. *Nature Reviews Neurology*. 2020 Jul 15;16(7):381-400.
10. Carter MJ, DaVanzo J, Haught R, Nusgart M, Cartwright D, Fife CE. Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019. *Journal of Medical Economics*. 2023 Dec 31;26(1):894-901.
11. Edwards RR, Schreiber KL, Dworkin RH, Turk DC, Baron R, Freeman R, Jensen TS, Latremoliere A, Markman JD, Rice AS, Rowbotham M. Optimizing and accelerating

- the development of precision pain treatments for chronic pain: IMMPACT review and recommendations. *The journal of pain*. 2023 Feb 1;24(2):204-25.
12. Fazmiya MJ, Sultana A, Rahman K, Heyat MB, Akhtar F, Khan S, Appiah SC. Current Insights on bioactive molecules, antioxidant, anti-inflammatory, and other pharmacological activities of *Cinnamomum camphora* Linn. *Oxidative Medicine and Cellular Longevity*. 2022 Oct 7;2022.
  13. Poddar S, Sarkar T, Choudhury S, Chatterjee S, Ghosh P. Indian traditional medicinal plants: A concise review. *International Journal of Botany Studies*. 2020;5(5):174-90.
  14. Pang D, Pucci M. Medical Aspects of Drug and Alcohol Use. In *Seminars in Addiction Psychiatry* 2021 Nov 4 (p. 175). Cambridge University Press.
  15. Malabadi RB, Kolkar KP, Meti NT, Chalannavar RK. An age-old botanical weapon for herbal therapy: Camphor tree, *Cinnamomum camphora*. *Int. J. Innov. Sci. Res*. 2021;3:1518-23.
  16. Guo S, Geng Z, Zhang W, Liang J, Wang C, Deng Z, Du S. The chemical composition of essential oils from *Cinnamomum camphora* and their insecticidal activity against the stored product pests. *International journal of molecular sciences*. 2016 Nov 4;17(11):1836.
  17. Pragadheesh VS, Saroj A, Yadav A, Chanotiya CS, Alam M, Samad A. Chemical characterization and antifungal activity of *Cinnamomum camphora* essential oil. *Industrial crops and products*. 2013 Aug 1;49:628-33.
  18. Shi S, Wu Q, Su J, Li C, Zhao X, Xie J, Gui S, Su Z, Zeng H. Composition analysis of volatile oils from flowers, leaves, and branches of *Cinnamomum camphora* var. *Borneol* in china. *Journal of Essential Oil Research*. 2013 Oct 1;25(5):395-401.
  19. Xu Y, Qin J, Wang P, Li Q, Yu S, Zhang Y, Wang Y. Chemical composition and larvicidal activities of essential oil of *Cinnamomum camphora* (L.) leaf against *Anopheles stephensi*. *Revista da Sociedade Brasileira de Medicina Tropical*. 2020 Jan 27;53:e20190211.
  20. Chalchat JC, Valade I. Chemical composition of leaf oils of *Cinnamomum* from Madagascar: *C. zeylanicum* Blume, *C. camphora* L., *C. fragrans* Baillon and *C. angustifolium*. *Journal of Essential Oil Research*. 2000 Sep 1;12(5):537-40.
  21. Stubbs BJ, Specht A, Brushett D. The essential oil of *Cinnamomum camphora* (L.) Nees and Eberm.—variation in oil composition throughout the tree in two chemotypes from eastern Australia. *Journal of Essential Oil Research*. 2004 Jan 1;16(1):9-14.
  22. Farivar M, Hooshmandi Z, Setorki M, Amini S. Protective Effect of 1, 8-cineole on Learning and Memory Impairment Induced by Cerebral Hypoperfusion in Male Rats. *Qom University of Medical Sciences Journal*. 2020 Jun 10;14(4):40-7.
  23. Moss M, Oliver L. Plasma 1, 8-cineole correlates with cognitive performance following exposure to rosemary essential oil aroma. *Therapeutic advances in psychopharmacology*. 2012 Jun;2(3):103-13.
  24. Fan LY, Lin Q, Yang NY, Chen LH. Analgesic Effects of the Essential Oil from *Cinnamomum camphora* Against Nitroglycerin-induced Migraine in Mice. *Indian Journal of Pharmaceutical Sciences*. 2020 Jan 1;82(1).
  25. Peana AT, Paolo SD, Chessa ML, Moretti MD, Serra G, Pippia P. (-)-Linalool produces antinociception in two experimental models of pain. *European journal of pharmacology*. 2003 Jan 26;460(1):37-41.

26. Wang S, Zhang D, Hu J, Jia Q, Xu W, Su D, Song H, Xu Z, Cui J, Zhou M, Yang J. A clinical and mechanistic study of topical borneol- induced analgesia. *EMBO Molecular Medicine*. 2017 Jun;9(6):802-15.
27. Zheng XB, Zhang YL, Li Q, Liu YG, Wang XD, Yang BL, Zhu GC, Zhou CF, Gao Y, Liu ZX. Effects of 1, 8-cineole on neuropathic pain mediated by P2X2 receptor in the spinal cord dorsal horn. *Scientific Reports*. 2019 May 27;9(1):7909.

UNDER PEER REVIEW

**Table 1 Assessment Of Degree Of Alertness And Learning Behaviour In The Test And Control Groups Using Passive Avoidance Test.**

Groups	Treatment	Week 1 Time (mean± SEM)	Week 2 Time (mean± SEM)	Week 3 Time (mean± SEM)
Group 1	Distilled water	120.60 ± 7.3	180.0 ± 73.5	132.40 ± 65.5
Group 2	0.2ml <i>Cinnamomum camphora</i>	197.0 ± 64.5	300.0* ± 0.0	240.0 ± 60.0
Group 3	0.4ml <i>Cinnamomum camphora</i>	187.20 ± 64.0	300.0* ± 0.0	300.0* ± 0.0
Group 4	0.6ml <i>Cinnamomum camphora</i>	70.20* ± 58.3	180.0 ± 73.5	160.60 ± 67.9
Group 5	0.5ml piroxicam	49.20 ± 18.6	180.0 ± 73.5	300.0* ± 0.0

Values are presented in mean ± SEM n=5, \* means values are statistically significant when compared to the control values (SEM= standard error mean)

**Table 2 Assessment Of Pain Bearance Threshold And Response In The Test And Control Groups Using Analgesymler**

Groups	Treatment	Week 1 Gram (mean±	Week 2 Gram (means±	Week 3 Gram (mean±
--------	-----------	-----------------------	------------------------	-----------------------

*Values are presented in mean ± SEM n=5, \* means values are statistically significant when compared to the control values(p<0.05).*

		SEM)	SEM)	SEM)
Group 1	Distilled water	10.20 ± 1.8	10.64 ± 3.9	10.64 ± 3.9
Groups2	Treatment <i>Cinnamomum camphora</i>	Week 1 14.20 ± 4.5 Time (mean ± SEM)	Week 2 19.82* ± 4.1 Time (mean ± SEM)	Week 3 9.46 ± 4.2 Time (mean ± SEM)
Group 3	0.4ml <i>Cinnamomum camphora</i>	7.0 ± 1.1	4.36 *± 0.4	8.50 ± 2.0
Group 4	0.6ml <i>Cinnamomum camphora</i>	6.16 *± 1.5	4.52 *± 0.7	4.52* ± 0.9
Group 5	0.5ml piroxicam	9.60 ± 3.9	23.90* ± 1.1	11.12 ± 3.4

**Table 3 Assessment Of Pain Sensitivity And Response Behaviour In The Test And Control Groups Using Tailclip Procedure.**

*Values are presented in mean ± SEM n=5, \* means values are statistically significant when compared to the control values.*

Group 1	Distilled water	15.80 ± 7.1	35.40 ± 21.9	35.40 ± 21.9
Group 2	0.2ml <i>Cinnamomum camphora</i>	28.0 ± 19.6	11.20 ± 4.9	13.0* ± 4.9
Group 3	0.4ml <i>Cinnamomum camphora</i>	21.80 ± 3.7	17.0 ± 4.3	14.0 ± 1.9
Group 4	0.6ml <i>Cinnamomum camphora</i>	16.60 ± 4.6	92.4* ± 53.3	85.0* ± 53.9
Group 5	0.5ml piroxicam	62.40 ± 27.2	10.40 ± 3.9	21.0 ± 10.7

UNDER PEER REVIEW